SCHEMBL2274795

SCHEMBL2274795

O=C(Nc1cc(-c2ccc3c(c2)OCO3)ccc1C(=O)O)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.60
RAB9A P51151 6/20 0.60
PTGS2 P35354 1/20 0.58
TDP2 O95551 1/20 0.57
CASP6 P55212 1/20 0.57
MAPT P10636 3/20 0.55
ACLY P53396 1/20 0.55
KMT2A Q03164 3/20 0.54
MEN1 O00255 2/20 0.54
PKM P14618 3/20 0.54
TDP1 Q9NUW8 2/20 0.54
GRIK1 P39086 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
FABP3 P05413 1/20 0.53
FABP4 P15090 1/20 0.53
FABP5 Q01469 1/20 0.53
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
TP53 P04637 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2271243 0.93 ADCY1 (0.61) NPC1RAB9AMAPTACLYKMT2A
SCHEMBL2272541 0.91 PTGS2 (0.63) NPC1RAB9APTGS2MAPTKMT2A
SCHEMBL2273182 0.90 PTGS2 (0.66) NPC1RAB9APTGS2MAPTACLY
SCHEMBL2272852 0.89 CASP3 (0.57) NPC1RAB9APTGS2KMT2AMEN1
SCHEMBL12369430 0.88 KDM4E (0.58) NPC1RAB9APTGS2TDP2CASP6
SCHEMBL2272940 0.87 NPC1 (0.62) NPC1RAB9APTGS2MAPTACLY
SCHEMBL2270231 0.85 CASP3 (0.59) NPC1RAB9APTGS2MAPTKMT2A
SCHEMBL2277756 0.84 PTGS2 (0.57) NPC1RAB9APTGS2MAPTACLY
SCHEMBL2276071 0.84 CA12 (0.58) NPC1RAB9APTGS2MAPTKMT2A
SCHEMBL2276083 0.84 CA12 (0.58) NPC1RAB9APTGS2MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 NPC1 4836/4885RAB9A 2238/4885PTGS2 486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.